Reports
Sale
Global In-Vitro Colorectal Cancer Screening Tests Market: By Test Type: Fecal Occult Blood Test (FOBT), Stool DNA Test (sDNA), Colonoscopy, Flexible Sigmoidoscopy, CT Colonography (Virtual Colonoscopy), Biomarker Tests; By Technology; By Collection Method; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global In-Vitro Colorectal Cancer Screening Tests Market Outlook
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, driven by the rising prevalence of colorectal cancer across 8 major markets. The market is expected to grow at a CAGR of 5.53% during the forecast period of 2024-2032, with the values likely to rise from USD 970.2 million in 2024 to USD 1492.8 million by 2032.
Global In-Vitro Colorectal Cancer Screening Tests Market Overview
Colorectal cancer (CRC) accounts for 10% of all cancer cases. Ranking as the third most common type of cancer, it is estimated that 3.2 million new colorectal cancer cases per year will arise by 2040. Early detection of the cancer is essential for the successful treatment of the disease. With the rising prevalence of colorectal cancer fuelling the demand for efficient and accurate diagnostic methods, the in-vitro colorectal cancer screening tests market demand is anticipated to experience a surge in the coming years.
Metastatic colorectal cancer is accountable for about 90% of the cancer fatalities. To facilitate early detection of cancer metastasis, scientists have deployed machine learning and artificial intelligence associated tools in diagnostic techniques. In November 2023, scientists investigated 11 biomarkers associated with metastatic CRC using a machine learning (ML) approach. Out of 11 biomarkers, 4 gained experimental validation, indicating the potential of machine learning in biomarker discovery. The integration of algorithms such as LASSO and P-SVM, helped in improving efficiency and accuracy of biomarker selection process.
In-vitro colorectal cancer screening tests market growth is also driven by intensive research initiatives aimed at improving colorectal cancer screening effectiveness and accessibility. These developments will positively impact early detection rates and improve patients, thereby propelling the demand for in-vitro colorectal cancer screening tests.
Global In-Vitro Colorectal Screening Tests Market Trends
| Key Trends | Description |
| Non-Invasive Testing | The evolving preference towards non-invasive screening tests, such as stool-based DNA tests and blood biomarker tests, offers a less intrusive alternative to traditional colonoscopies. |
| Molecular Diagnostics Growth | Advancements in molecular diagnostics are leading to the development of more accurate and sensitive tests. Such tests can detect genetic mutations associated with colorectal cancer, even at early stages. |
| AI and Machine Learning | The integration of artificial intelligence (AI) and machine learning technologies in analyzing test results and predicting risk levels is enhancing the precision and efficiency of colorectal cancer screening tests. |
| Multiplex Testing Platforms | The development of multiplex testing platforms capable of assessing multiple biomarkers simultaneously is improving the accuracy of colorectal cancer screening. Further, it enables more personalized risk assessment and monitoring strategies. |
Global In-Vitro Colorectal Cancer Screening Tests Market Segmentation
Market Breakup by Test Type
- Fecal Occult Blood Test (FOBT)
- Guaiac FOBT
- Immuno-FOBT (FIT)
- Stool DNA Test (sDNA)
- Colonoscopy
- Flexible Sigmoidoscopy
- CT Colonography (Virtual Colonoscopy)
- Biomarker Tests
- CEA Tests
- Other Blood-Based Tests
The market segmentation by test type includes fecal occult blood test (FOBT) which can be further segmented into guaiac and mmune variations. Stool DNA test (sDNA), colonoscopy, flexible sigmoidoscopy, CT colonography, and biomarker tests such as CEA and other blood-based tests. These diagnostic tests offer diverse approaches for early detection of colorectal cancer.
Market Breakup by Technology
- Tumor Biomarker-Based Tests
- Guaiac-Based Tests
- Immuno-FOBT (FIT)
- DNA-Based Tests
- Colonoscopy Technology
- Other Emerging Technologies
Based on technology, the market is divided into tumor biomarker-based tests, guaiac-based tests, Immuno-FOBT (FIT), DNA-based tests, and colonoscopy technology, among other emerging technologies. Technological advancements in screening methods are expected to boost the in-vitro colorectal cancer screening tests market size.
Market Breakup by Collection Method
- Guaiac Sampling
- Immuno-FOBT Sampling
- Stool DNA Sampling
- Blood Sampling (for Biomarker Tests)
- Others
The market is segmented by collection method into guaiac sampling, Immuno-FOBT sampling, stool DNA sampling, and blood sampling for biomarker tests, among others. This market segment ensures efficient and accurate sample collection in colorectal cancer screening.
Market Breakup by End User
- Hospitals
- Diagnostic Laboratories
- Ambulatory Surgical Centers
- Research Institutes
- Others
End users of the market encompass hospitals, diagnostic laboratories, ambulatory surgical centers, research institutes, and other facilities. Hospitals and diagnostic laboratories serve as primary centers for screening and diagnosis of colorectal cancer.
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market is segmented by region, covering North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is the leading player in the market, which can be attributed to the high incidence rate of colorectal cancer in the region which fuels the demand for screening tests. In addition, the presence of an advanced healthcare system and the rising geriatric population base is poised to support market growth in the region.
Global In-Vitro Colorectal Cancer Screening Tests Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Beckman Coulter, Inc. (a Danaher Company)
- Biohit Oyj
- Epigenomics AG
- Exact Sciences Corporation
- Hemosure, Inc.
- Randox Laboratories Ltd.
- QIAGEN N.V.
- Eiken Chemical Co., Ltd.
- Novigenix SA
- Sysmex Corporation
- Immundiagnostik AG
- Epi proColon (Epigenomics AG)
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Test Type |
|
| Breakup by Technology |
|
| Breakup by Collection Method |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Global In-Vitro Colorectal Cancer Screening Tests Market Report
- How is the market landscape expected to evolve in upcoming years?
- What are the major market trends influencing the market?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What technology type will dominate the in-vitro colorectal cancer screening tests market share?
- What type of collection methods are expected to dominate the respective market segment?
- Which applications are expected to significantly impact the growth of the market?
- Which test type in the market is expected to achieve high demand in the coming years?
- What are the key research initiatives expected to boost the market value during the forecast period?
- Which segment has the highest impact on the market size?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global In-Vitro Colorectal Cancer Screening Tests Market Overview
3.1 Global In-Vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
3.2 Global In-Vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
4 Global In-Vitro Colorectal Cancer Screening Tests Market Landscape*
4.1 Global In-Vitro Colorectal Cancer Screening Tests: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global In-Vitro Colorectal Cancer Screening Tests: Product Landscape
4.2.1 Analysis by Test Type
4.2.2 Analysis by Technology
5 Global In-Vitro Colorectal Cancer Screening Tests Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global In-Vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
6.1 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
6.1.1 Market Overview
6.1.2 Fecal Occult Blood Test (FOBT)
6.1.2.1 Guaiac FOBT
6.1.2.2 Immuno-FOBT (FIT)
6.1.3 Stool DNA Test (sDNA)
6.1.4 Colonoscopy
6.1.5 Flexible Sigmoidoscopy
6.1.6 CT Colonography (Virtual Colonoscopy)
6.1.7 Biomarker Tests
6.1.7.1 CEA Tests
6.1.7.2 Other Blood-Based Tests
6.2 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Tumor Biomarker-Based Tests
6.2.3 Guaiac-Based Tests
6.2.4 Immuno-FOBT (FIT)
6.2.5 DNA-Based Tests
6.2.6 Colonoscopy Technology
6.2.7 Other Emerging Technologies
6.3 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Collection Method
6.3.1 Market Overview
6.3.2 Guaiac Sampling
6.3.3 Immuno-FOBT Sampling
6.3.4 Stool DNA Sampling
6.3.5 Blood Sampling (for Biomarker Tests)
6.3.6 Others
6.4 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Diagnostic Laboratories
6.4.4 Ambulatory Surgical Centers
6.4.5 Research Institutes
6.4.6 Others
6.5 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
7.1 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
7.1.1 Market Overview
7.1.2 Fecal Occult Blood Test (FOBT)
7.1.2.1 Guaiac FOBT
7.1.2.2 Immuno-FOBT (FIT)
7.1.3 Stool DNA Test (sDNA)
7.1.4 Colonoscopy
7.1.5 Flexible Sigmoidoscopy
7.1.6 CT Colonography (Virtual Colonoscopy)
7.1.7 Biomarker Tests
7.1.7.1 CEA Tests
7.1.7.2 Other Blood-Based Tests
7.2 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Tumor Biomarker-Based Tests
7.2.3 Guaiac-Based Tests
7.2.4 Immuno-FOBT (FIT)
7.2.5 DNA-Based Tests
7.2.6 Colonoscopy Technology
7.2.7 Other Emerging Technologies
7.3 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
8.1 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
8.1.1 Market Overview
8.1.2 Fecal Occult Blood Test (FOBT)
8.1.2.1 Guaiac FOBT
8.1.2.2 Immuno-FOBT (FIT)
8.1.3 Stool DNA Test (sDNA)
8.1.4 Colonoscopy
8.1.5 Flexible Sigmoidoscopy
8.1.6 CT Colonography (Virtual Colonoscopy)
8.1.7 Biomarker Tests
8.1.7.1 CEA Tests
8.1.7.2 Other Blood-Based Tests
8.2 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Tumor Biomarker-Based Tests
8.2.3 Guaiac-Based Tests
8.2.4 Immuno-FOBT (FIT)
8.2.5 DNA-Based Tests
8.2.6 Colonoscopy Technology
8.2.7 Other Emerging Technologies
8.3 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
9.1 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
9.1.1 Market Overview
9.1.2 Fecal Occult Blood Test (FOBT)
9.1.2.1 Guaiac FOBT
9.1.2.2 Immuno-FOBT (FIT)
9.1.3 Stool DNA Test (sDNA)
9.1.4 Colonoscopy
9.1.5 Flexible Sigmoidoscopy
9.1.6 CT Colonography (Virtual Colonoscopy)
9.1.7 Biomarker Tests
9.1.7.1 CEA Tests
9.1.7.2 Other Blood-Based Tests
9.2 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Tumor Biomarker-Based Tests
9.2.3 Guaiac-Based Tests
9.2.4 Immuno-FOBT (FIT)
9.2.5 DNA-Based Tests
9.2.6 Colonoscopy Technology
9.2.7 Other Emerging Technologies
9.3 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
10.1 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
10.1.1 Market Overview
10.1.2 Fecal Occult Blood Test (FOBT)
10.1.2.1 Guaiac FOBT
10.1.2.2 Immuno-FOBT (FIT)
10.1.3 Stool DNA Test (sDNA)
10.1.4 Colonoscopy
10.1.5 Flexible Sigmoidoscopy
10.1.6 CT Colonography (Virtual Colonoscopy)
10.1.7 Biomarker Tests
10.1.7.1 CEA Tests
10.1.7.2 Other Blood-Based Tests
10.2 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Tumor Biomarker-Based Tests
10.2.3 Guaiac-Based Tests
10.2.4 Immuno-FOBT (FIT)
10.2.5 DNA-Based Tests
10.2.6 Colonoscopy Technology
10.2.7 Other Emerging Technologies
10.3 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
11.1 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
11.1.1 Market Overview
11.1.2 Fecal Occult Blood Test (FOBT)
11.1.2.1 Guaiac FOBT
11.1.2.2 Immuno-FOBT (FIT)
11.1.3 Stool DNA Test (sDNA)
11.1.4 Colonoscopy
11.1.5 Flexible Sigmoidoscopy
11.1.6 CT Colonography (Virtual Colonoscopy)
11.1.7 Biomarker Tests
11.1.7.1 CEA Tests
11.1.7.2 Other Blood-Based Tests
11.2 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Tumor Biomarker-Based Tests
11.2.3 Guaiac-Based Tests
11.2.4 Immuno-FOBT (FIT)
11.2.5 DNA-Based Tests
11.2.6 Colonoscopy Technology
11.2.7 Other Emerging Technologies
11.3 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Abbott Laboratories
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Siemens Healthineers AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Beckman Coulter, Inc. (a Danaher Company)
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Biohit Oyj
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Epigenomics AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Exact Sciences Corporation
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Hemosure, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Randox Laboratories Ltd.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 QIAGEN N.V.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Eiken Chemical Co., Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Novigenix SA
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Sysmex Corporation
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Immundiagnostik AG
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Epi proColon (Epigenomics AG)
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global In-Vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 920.4 million in 2023 driven by the rising prevalence of colorectal cancer across 8 major markets.
What is the global in-vitro colorectal cancer screening tests market forecast outlook for 2024-2032?
The market is anticipated to grow at a CAGR of 5.53% during the forecast period of 2024-2032, likely to reach a market value of USD 1492.8 million by 2032.
Intensive research initiatives aimed at improving colorectal cancer screening effectiveness and accessibility are fuelling the market demand. Rising preference for non-invasive screening tests is another vital factor.
One of the significant trends in the market is the rapid technological advancements including machine learning and artificial intelligence integration in the diagnostic techniques. In November 2023, scientists applied machine learning algorithms like LASSO and P-SVM to identify colorectal cancer biomarkers. It helped identify 11 biomarkers, out which 4 received experimental validation as well.
Based on the test type, the market is segmented into fecal occult blood test (FOBT), stool DNA test (sDNA), colonoscopy, flexible sigmoidoscopy, CT colonography, and biomarker tests.
Based on the technology, the market is divided into tumor biomarker-based tests, guaiac-based tests, immuno-FOBT (FIT), DNA-based tests, and colonoscopy technology, among other emerging technologies.
The market is segmented by collection method into guaiac sampling, immuno-FOBT sampling, stool DNA sampling, and blood sampling (for biomarker tests), among others.
End users of the market are hospitals, diagnostic laboratories, ambulatory surgical centers, research institutes, and other facilities.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Beckman Coulter, Inc. (a Danaher Company), Biohit Oyj, Epigenomics AG, Exact Sciences Corporation, Hemosure, Inc., Randox Laboratories Ltd., QIAGEN N.V., Eiken Chemical Co., Ltd., Novigenix SA, Sysmex Corporation, Immundiagnostik AG, and Epi proColon (Epigenomics AG).
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER